Want to see KR:008930 full AI Analyst Report?
008930 Stock Chart & Stats
₩42200.00
₩750.00(1.81%)
―
--
Day’s Range― - ―
52-Week Range₩25,600.00 - ₩63,800.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)230.61K
Market Cap
₩2.86T
Enterprise Value₩2.13T
Total Cash (Recent Filing)₩98.28B
Total Debt (Recent Filing)₩183.95B
Price to Earnings (P/E)19.3
Beta0.25
Next Earnings
Feb 11, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.42%
Share Statistics
EPS (TTM)2188.77
Shares Outstanding68,391,550
10 Day Avg. Volume245,853
30 Day Avg. Volume230,606
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)2.55
Price to Sales (P/S)1.82
P/FCF Ratio85.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue And Profitability ImprovementStrong TTM revenue growth alongside higher net margins indicates improving commercial performance and earnings power. If sustained, this combination can strengthen internal funding capacity, support investment across the pharmaceutical ecosystem, and provide a firmer base for results over the next several quarters.
Conservative Balance SheetLow leverage and a growing equity base give Hanmi Science meaningful financial flexibility relative to its current operations. Healthy returns on equity also suggest that the stronger capital position is being used productively, improving resilience and preserving capacity to support future growth initiatives.
Global Licensing OptionalityThe HM17321 licensing agreement expands access to global development and commercialization capabilities through a major multinational partner. Its upfront, milestone, and royalty structure could materially increase the group’s long-term pipeline value and international revenue potential if development succeeds.
Bears Say
Weak Cash ConversionProfit growth is not translating into cash at a comparable rate, creating a meaningful earnings-quality concern. Weak operating cash conversion and declining free cash flow could constrain internally funded investment, reduce flexibility during development spending, and make reported earnings less durable.
Moderate And Volatile Operating MarginsAlthough profitability has improved recently, the moderate EBIT margin and uneven historical margin progression indicate that earnings expansion is not yet consistently established. This may limit operating leverage and leave future results more dependent on revenue growth than on a steadily strengthening cost structure.
Licensing Deal Execution RiskThe large headline value of the HM17321 transaction is contingent rather than fully secured, because development, approval, commercialization, and antitrust conditions remain relevant. Delays or failure at these stages could defer milestones, reduce royalty potential, and limit the deal’s lasting contribution.
Hanmi Science Co., Ltd News
008930 FAQ
What was Hanmi Science Co., Ltd’s price range in the past 12 months?
Hanmi Science Co., Ltd lowest stock price was ₩25600.00 and its highest was ₩63800.00 in the past 12 months.
What is Hanmi Science Co., Ltd’s market cap?
Hanmi Science Co., Ltd’s market cap is ₩2.86T.
When is Hanmi Science Co., Ltd’s upcoming earnings report date?
Hanmi Science Co., Ltd’s upcoming earnings report date is Feb 11, 2027 which is in 104 days.
How were Hanmi Science Co., Ltd’s earnings last quarter?
Hanmi Science Co., Ltd released its earnings results on Oct 27, 2026. The company reported ₩227.718 earnings per share for the quarter.
Is Hanmi Science Co., Ltd overvalued?
According to Wall Street analysts Hanmi Science Co., Ltd’s price is currently Undervalued.
Does Hanmi Science Co., Ltd pay dividends?
Hanmi Science Co., Ltd pays a Notavailable dividend of ₩300 which represents an annual dividend yield of 1.42%. See more information on Hanmi Science Co., Ltd dividends here
What is Hanmi Science Co., Ltd’s EPS estimate?
Hanmi Science Co., Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hanmi Science Co., Ltd have?
Hanmi Science Co., Ltd has 68,391,550 shares outstanding.
What happened to Hanmi Science Co., Ltd’s price movement after its last earnings report?
Hanmi Science Co., Ltd reported an EPS of ₩227.718 in its last earnings report. Following the earnings report the stock price went down -2.012%.
Which hedge fund is a major shareholder of Hanmi Science Co., Ltd?
Currently, no hedge funds are holding shares in KR:008930
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hanmi Science Co., Ltd
Hanmi Science Co., Ltd. operates through its subsidiaries to produce and distribute pharmaceutical products both within South Korea and internationally. The company's research and development initiatives primarily target treatments for diabetes and various types of cancer. Its extensive product line further includes active pharmaceutical ingredients, general therapeutic drugs, nutritional supplements, and a variety of health-related goods and services. Additionally, it manages an online pharmacy platform and provides automated systems for pharmaceutical administration. The firm, which was initially established as Hanmi Holdings Co., Ltd. in 1973, adopted its current name, Hanmi Science Co., Ltd., in March 2012, and its corporate headquarters are situated in Seoul, South Korea.
Technical Analysis
Hanall Biopharma Co., Ltd.
―
Celltrion Pharm Inc.
―
Mezzion Pharma Co., Ltd.
―
ST PHARM CO., LTD.
―
SK bioscience Co.,Ltd.
―